Universal HPLC detector offers near nanogram sensitivity
NQAD is said to be a major advance in high-performance liquid chromatography detection
The NQAD is a different kind of aerosol-based detector for HPLC, the company says. Based on Condensation Nucleation (CNLSD) technology, the NQAD has the ability to detect sub-nanogram levels.
Benefiting from ultra-high sensitivity, the detector is suitable for searching for drug impurities, degradation products, excipients and when industrial hygiene is a concern. Both easy and hard-to-measure compounds can be quantified accurately with minimal sample preparation, the company says.
The NQAD detector also offers a wide dynamic range with superior linearity compared with other aerosol-based detectors. Chromophores and fluorophores are not needed for detection, thereby eliminating or decreasing the need for compound derivatisation. The detector is optimised for use in UHPLC, HPLC and SFC.
The company says it is easy to install and operate and therefore ideal for use in any laboratory.
You may also like
Trending Articles
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
The path to commercial allogeneic iPSC therapies
The cell therapy sector is currently shifting from patient-specific autologous treatments toward off-the-shelf allogeneic cell therapies. Although this transition is helping to democratise access to treatments, it introduces several challenges in terms of controlling complex biology at a commercial scale
Manufacturing
Safety in pharmaceutical manufacturing: why a trusted partner makes all the difference
By taking a three-tiered approach to protecting patients and personnel and ensuring plant compliance, GEA adopts a consultative approach to helping its customers navigate the responsibilities of pharmaceutical manufacturing safety with confidence
Research & Development
The IND advantage: why early derisking is a strategic imperative for complex biologics
As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
Research & Development
Stipple Bio enters into multi-target license agreement with Lonza to advance precision oncology ADC therapies
Stipple Bio’s Pointillist Platform identifies tumour-specific cell surface epitopes that, when combined with Lonza’s clinically validated ADC platform, may enable first-in-class and best-in-class ADC oncology medicines such as STP-100
Manufacturing
Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb as part of ongoing strategic collaboration
CRDMO successfully scaled and transferred Renaissance Pharma’s lead candidate, Daretabart a humanised monoclonal antibody targeting GD2 for high-risk neuroblastoma, in just 9 months
Research & Development
Lonza advances integrated DNA‑to‑IND programmes with acceleration, derisking and innovation
New GS Ori‑Go vector technology supports titers higher than 11 g/L and reliable bulk pool stability, enabling more predictable material generation and shortened cell line development timelines